HDAC9 and acute myeloid leukemia: The JALSG AML201 trial (3) demonstrated that the lower-dose cytarabine (200 mg/m2 d1-d5) regimen combined with mitoxantrone, daunorubicin, aclarubicin, or etoposide was as effective as HDAC (2 g/m2 twice daily for 5 days) in postremission consolidation, and recommended that the conventional multiagent chemotherapy may be suitable for the AML patients in intermediate or adverse cytogenetic risk groups.